Copyright © 1999 by the European Society of Cardiology.
Increasing the impact of cardiological treatments. How best to reduce deaths
a Department of Public Health, University of Glasgow, Glasgow, Scotland, U.K.
c The Clinical Research Initiative in Heart Failure, University of Glasgow, Glasgow, Scotland, U.K.
b Department of Public Health, Greater Glasgow Health Board, Glasgow, Scotland, U.K.
revised April 4, 1999; accepted April 7, 1999 1999
Abstract
Aims To determine the extent to which increases in the uptake of effective treatments could further reduce coronary heart disease mortality in Scotland.
Methods and Results A cohort-based mortality model combining effectiveness data from published meta-analyses with available information on uptake of all coronary heart disease treatments in all patient categories in Scotland (population 5·1 million). In 1994, medical and surgical coronary disease treatments prevented or postponed an estimated 2722 deaths (minimum estimate 1373, maximum estimate 5986). Increasing treatment uptake to 100% of all eligible patients was considered unrealistic. Increasing uptake to 80% would have prevented or postponed a further 4078 deaths (39% from increases in secondary prevention therapies, 29%, 13%, 10% and 9% from the treatments of heart failure, acute myocardial infarction, hypertension and angina respectively).
Conclusions Many eligible patients are currently not receiving treatment that is effective in reducing coronary heart disease mortality. Increasing treatment uptake could prevent or postpone a further 4080 deaths each year in Scotland, approximately, more than doubling the present benefit from treatment. By implication, about 30000 additional deaths could be prevented, annually, in the U.K. Comparable symptom and morbidity benefits might also be expected. Future clinical audit activities should focus particularly on secondary prevention and heart failure treatments.
Key Words: Mortality, cardiology, treatment, audit coronary heart disease
f1 Correspondence: Dr Simon Capewell, University of Glasgow, Department of Public Health, 1 Lilybank Gardens, Glasgow G12 8RZ, Scotland.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N F Murphy, S Stewart, C L Hart, K MacIntyre, D Hole, and J J V McMurray A population study of the long-term consequences of Rose angina: 20-year follow-up of the Renfrew-Paisley study Heart, December 1, 2006; 92(12): 1739 - 1746. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Kabir, K. Bennett, E. Shelley, B. Unal, J. Critchley, J. Feely, and S. Capewell The population mortality benefits of maximizing the number of eligible patients receiving appropriate cardiology treatments in Ireland QJM, August 1, 2006; 99(8): 523 - 530. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Bennett, Z. Kabir, B. Unal, E. Shelley, J. Critchley, I. Perry, J. Feely, and S. Capewell Explaining the recent decrease in coronary heart disease mortality rates in Ireland, 1985-2000. J Epidemiol Community Health, April 1, 2006; 60(4): 322 - 327. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Laatikainen, J. Critchley, E. Vartiainen, V. Salomaa, M. Ketonen, and S. Capewell Explaining the Decline in Coronary Heart Disease Mortality in Finland between 1982 and 1997 Am. J. Epidemiol., October 15, 2005; 162(8): 764 - 773. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Unal, J. A. Critchley, and S. Capewell Explaining the Decline in Coronary Heart Disease Mortality in England and Wales Between 1981 and 2000 Circulation, March 9, 2004; 109(9): 1101 - 1107. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J A Critchley and S Capewell Substantial potential for reductions in coronary heart disease mortality in the UK through changes in risk factor levels J Epidemiol Community Health, April 1, 2003; 57(4): 243 - 247. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.A. Critchley and S. Capewell Why model coronary heart disease? Eur. Heart J., January 2, 2002; 23(2): 110 - 116. [Full Text] [PDF]
|
|
|
|
|
|
H.M. Krumholz Gaps and opportunities in the practice of medicine: the need for improved systems of care Eur. Heart J., June 1, 2001; 22(11): 889 - 890. [PDF]
|
|
|
|
|
|
C Hengstenberg, S.R Holmer, B Mayer, S Engel, A Schneider, H Lowel, G.A.J Riegger, and H Schunkert Siblings of myocardial infarction patients are overlooked in primary prevention of cardiovascular disease Eur. Heart J., June 1, 2001; 22(11): 926 - 933. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Z. Ayanian and T. J. Quinn Quality Of Care For Coronary Heart Disease In Two Countries Health Aff., May 1, 2001; 20(3): 55 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Capewell, R. Beaglehole, M. Seddon, and J. McMurray Explanation for the Decline in Coronary Heart Disease Mortality Rates in Auckland, New Zealand, Between 1982 and 1993 Circulation, September 26, 2000; 102(13): 1511 - 1516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. CAPEWELL and J. MCMURRAY Coronary heart disease trends in France and elsewhere Heart, August 1, 2000; 84(2): 121 - 122. [Full Text] [PDF]
|
|
|
|
|
|
H. Rosolova and J. Simon Editorials: Potential to reduce death by cardiological treatment Eur. Heart J., October 1, 1999; 20(19): 1376 - 1377. [PDF]
|
|